Tower Research Capital LLC TRC Takes Position in Grail, Inc. (NASDAQ:GRAL)

Tower Research Capital LLC TRC bought a new position in shares of Grail, Inc. (NASDAQ:GRAL - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 15,305 shares of the company's stock, valued at approximately $273,000.

Other institutional investors have also recently added to or reduced their stakes in the company. FNY Investment Advisers LLC acquired a new position in shares of Grail during the fourth quarter worth $26,000. Lindbrook Capital LLC acquired a new position in Grail during the 4th quarter worth about $28,000. Sterling Capital Management LLC acquired a new position in Grail during the 4th quarter worth about $29,000. Wellington Shields Capital Management LLC acquired a new stake in shares of Grail in the fourth quarter valued at about $33,000. Finally, Teachers Retirement System of The State of Kentucky bought a new position in shares of Grail during the fourth quarter worth about $54,000.

Grail Stock Up 10.1 %

NASDAQ GRAL opened at $35.78 on Friday. Grail, Inc. has a one year low of $12.33 and a one year high of $63.99. The business has a 50 day simple moving average of $30.08 and a 200 day simple moving average of $25.08.

Grail (NASDAQ:GRAL - Get Free Report) last released its quarterly earnings data on Thursday, February 20th. The company reported ($1.86) earnings per share for the quarter, beating the consensus estimate of ($4.41) by $2.55. The company had revenue of $38.25 million during the quarter, compared to the consensus estimate of $35.33 million. On average, equities analysts predict that Grail, Inc. will post -15.15 EPS for the current year.

Analyst Upgrades and Downgrades

GRAL has been the subject of a number of recent analyst reports. Morgan Stanley increased their target price on shares of Grail from $16.00 to $20.00 and gave the company an "equal weight" rating in a research report on Tuesday, March 18th. Canaccord Genuity Group started coverage on shares of Grail in a research note on Monday, April 21st. They set a "buy" rating and a $32.00 target price for the company.

Insider Transactions at Grail

In other Grail news, President Joshua J. Ofman sold 2,109 shares of the stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $31.20, for a total value of $65,800.80. Following the transaction, the president now owns 559,673 shares in the company, valued at approximately $17,461,797.60. This represents a 0.38 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Robert P. Ragusa sold 7,625 shares of the firm's stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $31.21, for a total value of $237,976.25. Following the completion of the sale, the chief executive officer now directly owns 828,662 shares of the company's stock, valued at $25,862,541.02. This trade represents a 0.91 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 11,550 shares of company stock valued at $360,436 in the last 90 days.

Grail Profile

GRAIL, Inc is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.

Want to see what other hedge funds are holding GRAL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Grail, Inc. (NASDAQ:GRAL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.